Kennan Marsh

Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome

Barbara L. Cool, Bradley A. Zinker, William J. Chiou et al. · Cell Metabolism · 2006 · 904 citations · Full text

Metabolic Syndrome, Signal Transduction, Biochemistry +12

Potent, Orally Active Heterocycle-Based Combretastatin A-4 Analogues:  Synthesis, Structure−Activity Relationship, Pharmacokinetics, and In Vivo Antitumor Activity Evaluation

Le Wang, Keith W. Woods, Qun Li et al. · Journal of Medicinal Chemistry · 2002 · 420 citations · Full text

Medicinal Chemistry, Drug Targeting, Oncology +14

New inhibitors of renin that contain novel phosphostatine Leu-Val replacements

Joseph F. Dellaria, Robert G. Maki, Herman H. Stein et al. · Journal of Medicinal Chemistry · 1990 · 101 citations · Full text

Pharmaceutical Science, Renin Inhibitors, New Inhibitors +17

Zotarolimus, a Novel Sirolimus Analogue With Potent Anti-proliferative Activity on Coronary Smooth Muscle Cells and Reduced Potential for Systemic Immunosuppression

Yung‐Wu Chen, Morey L. Smith, Michael P. Sheets et al. · Journal of Cardiovascular Pharmacology · 2007 · 80 citations

Systemic Immunosuppression, Vivo Half-life, Immunology +16

Hepatic Glucocorticoid Receptor Antagonism Is Sufficient to Reduce Elevated Hepatic Glucose Output and Improve Glucose Control in Animal Models of Type 2 Diabetes

Peer B. Jacobson, Thomas W von Geldern, Lars Öhman et al. · Journal of Pharmacology and Experimental Therapeutics · 2005 · 77 citations · Full text